Atlas Trials

Treatment With Dinutuximab Beta, Zoledronic Acid and Low-dose Interleukin (IL-2) in Patients With Leiomyosarcoma

Clinical trial NCT05080790 · COMPLETED

Trial details

NCT number
NCT05080790
Sponsor
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Leiomyosarcoma
Start date
2021-11-15
Primary completion
2025-01-20
Enrollment
7

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.